Gene therapy deal dubbed a paradigm shift for bioengineering in India

The Indian Institute of Technology Kanpur (IITK) has entered into a Memorandum of Agreement (MOA) with Laurus Labs (NSE: LAURUSLABS) to introduce gene therapy assets to the market.

This collaboration has been described as a ‘paradigm shift’ with regards to innovation and advancement in the field of bioengineering in India, as an unprecedented industry-first investment in a faculty research group.

According to the MOA, IIT Kanpur will transfer several gene therapy assets through in-licensing to Laurus Labs, which will provide a research grant to facilitate their progression through pre-clinical development.